Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition characterized by pelvic pain and lower urinary tract symptoms. The evolution of nomenclature of IC/BPS has experienced a long history. The disease etiology is not yet fully understood; potential pathophysiologic causes proposed include defect of layer of glycosaminoglycan (GAG) on the apical surface of bladder floor; autoimmune, inflammatory, and neurogenic mechanisms; infection; and so on. There are a lot of strategies to cure IC/BPS, mainly including behavioral therapy, oral medicines, intravesical treatments, and intradetrusor botulinum toxin A (BTXA) injection. But none of them is curative. Most treatments are aimed at controlling symptom and improving the quality of life of patients. In this article, we will talk about the new progress of definition, etiology, and treatment on IC/BPS.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society.
Oravisto KJ. Epidemiology of interstitial cystitis. Annales chirurgiae et gynaecologiae Fenniae. 1974.
CK Payne GFJ, M Wise JQC. Interstitial cystitis and painful bladder syndrome. 2007.
JQ Clemens RTM, MCOK ROSETTI SYG. Prevalence and incidence of interstitial cystitis in a managed care population. 2005.
SH Berry LMB, C Pham KL, Nyberg L. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. 2010.
AM Suskind SHB, BA Ewing MNE. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. 2013.
Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.
Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.
Clemens JQ, Meenan RT, O’Keeffe-Rosetti MC, Gao SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like symptoms in a managed care population. J Urol. 2006;176(2):593–6. discussion 596.
Mehik A, Hellstrom P, Lukkarinen O, Sarpola A, Jarvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int. 2000;86(4):443–8.
Skene A. Diseases of the bladder and urethra in women. Am J Med Sci. 1879.
Hünner GL. A rare type of bladder ulcer in women. Tr. South. Surg. Gynecol. Assoc.. 1914.
DJ Clauw MS, D Radulovic AS. The relationship between fibromyalgia and interstitial cystitis. 1997.
Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg Jr L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161(2):553–7.
•Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 1988;140(1):203–6. Covers the classic criteria of interstitial cystitis/bladder pain syndrome (IC/BPS).
Hanno P, Dmochowski R. Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn. 2009;28(4):274–86.
van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.
Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol. 2007;14(12):1068–70.
•Homma Y. Hypersensitive bladder: a solution to confused terminology and ignorance concerning interstitial cystitis. Int J Urol. 2014;21 Suppl 1:43–7. Article covers new term drawing a distinction between interstitial cystitis and IC-like patients.
Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. Philos Trans R Soc Lond B Biol Sci. 1974;268(891):23–38.
Hurst RE, Meerveld BG, Wisniewski AB, et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. Transl Androl Urol. 2015;4(5):563–71.
••Kreft ME, Sterle M, Veranic P, Jezernik K. Urothelial injuries and the early wound healing response: tight junctions and urothelial cytodifferentiation. Histochem Cell Biol. 2005;123(4–5):529–39. Defect of GAG layer is the most famous hypothesis of IC/BPS, and it provides theoretical basis for GAG layer replenishment treatment.
Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK, Southgate J. PPARgamma-regulated tight junction development during human urothelial cytodifferentiation. J Cell Physiol. 2006;208(2):407–17.
Buckley MS, Washington S, Laurent C, Erickson DR, Bhavananadan VP. Characterization and immunohistochemical localization of the glycoconjugates of the rabbit bladder mucosa. Arch Biochem Biophys. 1996;330(1):163–73.
Stanford EJ, Dell JR, Parsons CL. The emerging presence of interstitial cystitis in gynecologic patients with chronic pelvic pain. Urology. 2007;69(4 Suppl):53–9.
Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–9.
Janssen DA, van Wijk XM, Jansen KC, van Kuppevelt TH, Heesakkers JP, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol. 2013;189(1):336–42.
Erickson DR, Herb N, Ordille S, Harmon N. A new direct test of bladder permeability. J Urol. 2000;164:419–22.
Towner RA, Wisniewski AB, Wu DH, et al. A feasibility study to determine whether clinical contrast enhanced magnetic resonance imaging can detect increased bladder permeability in patients with interstitial cystitis. J Urol. 2015.
Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990.
Said JW, Van de Velve R, Gillespie L. Immunopathology of interstitial cystitis. 1989.
Keay S, Zhang CO, Trifillis AL, Hebel JR, Jacobs SC. Urine autoantibodies in interstitial cystitis. 1997.
Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 2012;61:193–200.
Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One. 2013;8(8), e72067.
Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112(5):543–7.
Peters KM, Killinger KA, Ibrahim IA. Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome. Urology. 2009;73(2):258–62.
Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90.
Zhang QH, Shen XC, Zhou ZS, Chen ZW, Lu GS, Song B. Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. Int Urogynecol J. 2010;21(1):103–9.
Rosen JM, Klumpp DJ. Mechanisms of pain from urinary tract infection. Int J Urol. 2014;21 Suppl 1:26–32.
Verit A, Guner ND. Helicobacter pylori and urinary system stones: endoluminal damage as sub-hypothesis to support the current stone theory. Med Hypotheses. 2014;83(6):677–80.
Staack A, Distelberg B, Schlaifer A, Sabate J. Prospective study on the effects of regular and decaffeinated coffee on urinary symptoms in young and healthy volunteers. Neurourol Urodyn. 2015.
AN Pierce JAC. Chapter seventeen—stress and chronic pelvic pain. Progress in molecular biology and translational science. 2015.
Lee UJ, Ackerman AL, Wu A, et al. Chronic psychological stress in high-anxiety rats induces sustained bladder hyperalgesia. Physiol Behav. 2015;139:541–8.
Foster Jr HE, Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–8.
Dinis S, de Oliveira JT, Pinto R, Cruz F, Buffington CT, Dinis P. From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. Int J Womens Health. 2015;7:735–44.
Yang W, Propert KJ, Richard LJ. Estimating the efficacy of an interstitial cystitis/painful bladder syndrome medication in a randomized trial with both non-adherence and loss to follow-up. Stat Med. 2014;33(20):3547–55.
Sun Y, Fang Z, Ding Q, Zheng J. Effect of amitriptyline in treatment interstitial cystitis or bladder pain syndrome according to two criteria: does ESSIC criteria change the response rate. Neurourol Urodyn. 2014;33(3):341–4.
Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J Urol. 1987;138(3):503–7.
Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810–5.
Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology. 1990;35(6):552–8.
Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993;150(3):845–8.
Nickel JC, Herschorn S, Whitmore KE, et al. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62.
Giannantoni A, Bini V, Dmochowski R, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.
Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–9.
Yamada Y, Nomiya A, Niimi A, et al. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol. 2015;4(5):486–90.
Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–20.
Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective. Transl Androl Urol. 2015;4(6):600–4.
Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–5. discussion 1915–6.
Tomoe H. Editorial Comment from Dr Tomoe to botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22(9):841–2.
Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61–5.
Hung MJ, Chen YT, Shen PS, Hsu ST, Chen GD, Ho ES. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–9.
Gafni-Kane A, Botros SM, Du H, Sand RI, Sand PK. Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2013;24(2):303–11.
Cervigni M. Interstitial cystitis/bladder pain syndrome and glycosaminoglycans replacement therapy. Transl Androl Urol. 2015;4(6):638–42.
Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology. 1997;49(5A Suppl):111–3.
Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater. 2015;19:66–75.
Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2011;22(4):401–5.
Parsons CL, Koziol JA, Proctor JG, Zupkas P, Argade S. Heparin and alkalinized lidocaine versus alkalinized lidocaine for treatment of interstitial cystitis symptoms. Can J Urol. 2015;22(2):7739–44.
Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886–94.
Henry RA, Morales A, Cahill CM. Beyond a simple anesthetic effect: lidocaine in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Urology. 2015;85(5):1025–33.
Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. Int J Urol. 2013;20(11):1118–22.
Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71(1):67–70.
Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–12.
Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Int J Urol. 2014;21 Suppl 1:49–55.
Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–71.
Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.
Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2015.
Pinto R, Lopes T, Silva J, Silva C, DInis P. Clinical response to intra-trigonal onabotulinum toxin A injections is not related to the presence of ulcers in bladder pain syndrome/interstitial cystitis patient. 2013 AUA abstract. 2013.
HC Kuo MBC. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009 .
Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis—clinical results and immunohistochemistry analysis. Urology. 2013. 82(6): 1452.e1-6.
Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. Toxins (Basel). 2015;7(10):4283–93.
Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013;16(1):E15–23.
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 875.
Hanno PM, Sant GR. Clinical highlights of the National Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology. 2001;57(6 Suppl 1):2–6.
Adamowicz J, Pokrywczynska M, Drewa T. Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials. Med Hypotheses. 2014;82(6):670–3.
Song M, Lim J, Yu HY, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.
Colaco MA, Evans RJ. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome. Curr Urol Rep. 2013;14(5):442–7.
Zacche MM, Srikrishna S, Cardozo L. Novel targeted bladder drug-delivery systems: a review. Res Rep Urol. 2015;7:169–78.
Rajaganapathy BR, Chancellor MB, Nirmal J, Dang L, Tyagi P. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10(3), e0122766.
Lander EB, See JR. Intravesical instillation of pentosan polysulfate encapsulated in a liposome nanocarrier for interstitial cystitis. Am J Clin Exp Urol. 2014;2(2):145–8.
Gong C, Qi T, Wei X, et al. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem. 2013;20(1):79–94.
Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra100.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Drs. Xu and Fang have no conflicts of interest to declare.
Human and Animal Rights and Informed Consent
This article does not contain studies with human or animal subjects performed by the author.
Additional information
This article is part of the Topical Collection on Post-Prostatectomy and Acquired Voiding Dysfunction
Rights and permissions
About this article
Cite this article
Fang, Z., Xu, K. Interstitial Cystitis/Bladder Pain Syndrome: a Review and an Update. Curr Bladder Dysfunct Rep 11, 391–398 (2016). https://doi.org/10.1007/s11884-016-0387-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11884-016-0387-y